Gantenerumab Shows Positive Outcome in Reducing Amyloid Plaque Burden: NEJM Jacinthlyn Sylvia4 Dec 2023 11:00 PM ISTThe two phase 3 trials, GRADUATE I and II, explored the potential of gantenerumab, a monoclonal antibody targeting amyloid-beta, in slowing cognitive...
Roche to stop all Gantenerumab studies in early Alzheimer's disease Ruchika Sharma2 Dec 2022 2:30 PM ISTRoche is still testing a different formulation of gantenerumab called trontinemab, designed to ferry the drug across the blood brain barrier -...
Roche Alzheimer's drug gantenerumab fails to meet goal in long-awaited trial Ruchika Sharma14 Nov 2022 5:30 PM ISTBasel: Roche today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to...
Alzheimer's drug price will be competitive: Roche executive Ruchika Sharma13 Nov 2021 10:00 AM ISTNew Delhi: Roche Holding AG, still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking aim at rival...
Roche Gantenerumab gets USFDA Breakthrough Therapy Designation Ruchika Sharma11 Oct 2021 12:15 PM ISTBasel: Roche has recently announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted...
